Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. Such organizations are often creating barriers to access, such as high expense requirements and approval processes that limit user opportunity. Industry suggest that such